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Nucleostemin (NS) is a nucleolar protein expressed in adult and embryo-derived stem cells, transformed cell lines, and
tumors. NS decreases when proliferating cells exit the cell cycle, but it is unknown how NS is controlled, and how it
participates in cell growth regulation. Here, we show that NS is down-regulated by the tumor suppressor p14ARF and that
NS knockdown elevates the level of tumor suppressor p53. NS knockdown led to G1 cell cycle arrest in p53-positive cells
but not in cells in which p53 was genetically deficient or depleted by small interfering RNA knockdown. These results
demonstrate that, in the cells investigated, the level of NS is regulated by p14ARF and the control of the G1/S transition
by NS operates in a p53-dependent manner.
INTRODUCTION
Destabilization or inactivation of the tumor suppressor
p53 is typically required to maintain cell proliferation
(Vogelstein et al., 2000). However, it is unclear which of
many potential upstream regulators of p53 is responsible
for cell cycle progression or exit. Nucleostemin (NS) is a
nucleolar protein discovered in adult rat brain stem cells, and
it is also preferentially expressed in embryo-derived stem cells,
transformed cell lines, and human tumors (Tsai and McKay,
2002; Baddoo et al., 2003; Liu et al., 2004; Politz et al., 2005). NS
dynamically shuttles between the nucleolus and nucleoplasm,
and this exchange is based on its state of GTP binding (Tsai and
McKay, 2005). Pull-down and coimmunoselection experiments
reveal that NS interacts with p53 (Tsai and McKay, 2002), but
whether NS controls cell proliferation in a p53-dependent man-
ner remains unclear.
In a previous investigation, we found that the NS is concen-
trated in regions of the nucleolus that are relatively devoid of
nascent ribosomes (Politz et al., 2005). We subsequently asked
whether any other cell cycle progression-related proteins might
occupy this same intranucleolar territory, and we found that
the tumor suppressor p14ARF (alternate reading frame ARF)
precisely colocalizes with NS in these ribosome-sparse nucle-
olar regions (Supplemental Figure 1). Like NS, ARF is linked to
p53, and yet NS and ARF play opposite roles in cell prolifera-
tion. These initial findings, therefore, motivated us to investi-
gate whether ARF might regulate NS, and we found that it
does. In turn, this led to the finding that NS regulates cell cycle
progression via the p53 pathway.
MATERIALS AND METHODS
Cell Culture and Transfection
U2OS, Saos-2, and HeLa cells were cultured at 37°C in DMEM supplemented
with 10% fetal bovine serum (FBS). The NARF6 cell line (Stott et al., 1998) was
maintained in DMEM containing 10% FBS, 150 g/ml hygromycin, and 300
g/ml Geneticin (G-418; Invitrogen, Carlsbad, CA). For transient transfec-
tions, cells were plated in 35-mm dishes, and plasmid DNA was introduced
using Lipofectamine 2000 (Invitrogen) according to the manufacturer’s pro-
tocols. ARF expression in NARF6 cells was induced by the addition of
isopropyl--d-thiogalactopyranoside at 1 mM for 48 h. For analysis of cell
cycle progression, U2OS and Saos-2 cells were exposed to 10 M 5-bromode-
oxyuridine (BrdU) for 24 h, and incorporation was determined by immuno-
staining (see below).
Plasmids
Human NS cDNA was cloned from HeLa cell total RNA (Stratagene, La Jolla,
CA) by reverse transcription-polymerase chain reaction and cloned into the
pmRFP-C1 vector (Campbell et al., 2002) at the XhoI and HindIII sites,
resulting in the plasmid pmRFP-hNS-C1. Human ARF cDNA was cloned into
the pEGFP-N1 vector (Clontech, Mountain View, CA) at the XhoI and HindIII
sites, resulting in the plasmid pEGFP-ARF-N1. The plasmid pARF-N1 was
generated by insertion of human ARF cDNA into pEGFP-N1 at the BamHI
and NotI sites, resulting in excision of the enhanced green fluorescent protein
(EGFP) coding sequence.
Small Interfering RNA (siRNA) Knockdown
The siRNA sequence used for depletion of human NS was that described by
Tsai and McKay (2002). The other siRNA sequences used were human ARF:
GCUUCCUAGAAGACCAGGUdTdT; human p53: AAGACUCCAGUG-
GUAAUCUACdTdT; and human retinoblastoma-associated protein (Rb):
GAUACCAGAUCAUGUCAGAdTdT.
The nontargeting siCONTROL siRNA (Dharmacon RNA Technologies,
Lafayette, CO) was used as a negative control. siRNAs were purchased as
duplexes from Dharmacon RNA Technologies and transfected using Lipo-
fectamine 2000 (Invitrogen) according to the manufacturer’s protocols.
Immunofluorescence
Cells grown on coverslips were fixed for 12 min in phosphate-buffered saline
(PBS) containing 4% formaldehyde, and washed twice in PBS, followed by
permeabilization with 0.5% Triton X-100 for 5 min. Coverslips were then
incubated with primary antibodies in PBS-1% bovine serum albumin for 1 h
and washed three times with PBS before 1-h incubation with the appropriate
secondary antibodies, and finally washed three times with PBS. All these
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steps were carried out at room temperature. Coverslips were mounted in
Prolong Antifade (Invitrogen), and two- or three-dimensional images were
captured and in some cases subjected to deconvolution as described previ-
ously (Politz et al., 2005). The antibodies and dilutions used were as follows:
rabbit anti-human NS polyclonal antibody (1:200; Chemicon International,
Temecula, CA), mouse anti-human p14ARF monoclonal antibody (mAb)
4C6/4 (1:400, Abcam, Cambridge, MA), mouse anti-human p53 mAb DO-1
(1:100; Santa Cruz Biotechnology, Santa Cruz, CA), mouse anti-human
MDM2 mAb SMP-14 (1:50; Santa Cruz Biotechnology), and mouse anti-
human Rb mAb G3-245 (1:50; BD Biosciences, San Jose, CA).
In the BrdU experiments, cells were fixed in ice-cold methanol for 15 min,
and then they were immunostained for NS as described above. The coverslips
were then refixed and incubated in 4 N HCl for 20 min at room temperature,
and incorporation of BrdU was detected by immunostaining with mouse
anti-BrdU mAb 3D4 (1:250; BD Biosciences). The percentage of BrdU-labeled
nuclei was determined.
Immunoblotting
Cells were lysed on ice in 150 mM NaCl, 1% NP-40, 0.5% sodium deoxy-
cholate, 0.1% SDS, and 50 mM Tris-HCl, pH 7.4 containing a protease inhib-
itor cocktail (Roche Diagnostics, Indianapolis, IN) as specified by the manu-
facturer. Protein concentration was determined using the BCA assay (Pierce
Chemical, Rockford, IL). Samples were boiled with 2 Laemmli buffer and
electrophoresed on 10% polyacrylamide gels containing 0.1% SDS, followed
by transfer to Immobilon-P membranes (Millipore, Billerica, MA), and then
they were incubated with specific primary antibodies. Proteins of interest
were detected with appropriate horseradish peroxidase-conjugated second-
ary antibodies and enhanced chemiluminescence substrate (Pierce Chemical).
The antibodies used were rabbit anti-human nucleostemin (1:5000; Chemicon
International), mouse anti-human p14ARF (4C6/4, 1:500; Abcam), mouse anti-
human p53 (DO-1, 1:500), and mouse anti-human transferrin receptor (clone
H68.4, 1:1000; Zymed, South San Francisco, CA). Reactive bands of interest
were quantified by densitometry.
RESULTS AND DISCUSSION
U2OS is a human osteosarcoma cell line that does not
express ARF. When either ARF-GFP or ARF itself was
expressed in U2OS cells, the level of NS significantly
declined (Figure 1A). Western blotting showed that ARF
expression decreased the level of NS by 50% in the cell
population (Figure 1C). Conversely, the level of NS be-
came elevated when endogenous ARF was knocked down
in HeLa cells (Figure 1B). Thus, the level of nucleostemin
responds to either an increase or decrease in ARF. Because
knockdown of NS did not affect the level of ARF in HeLa
cells (data not shown), it would seem that ARF is an
upstream regulator of NS.
NS is thought to interact with p53 (Tsai and McKay, 2002)
whereas ARF is known to stabilize p53 by binding MDM2, a
ubiquitin ligase that normally degrades p53 (Haupt et al.,
1997; Kubbutat et al., 1997; Stott et al., 1998). To examine the
possible links among ARF, NS, and p53, we used the U2OS-
derived cell line NARF6, in which ARF expression is induc-
ible (Stott et al., 1998). Expression of ARF in NARF6 cells
resulted in a pronounced increase of p53 and a significant
decline of NS (Figure 2A). This result does not distinguish
between a direct action of ARF that destabilizes NS versus
an indirect effect in which ARF stabilizes p53 (vide supra),
which causes NS to be destabilized. To determine whether
the level of NS is related to that of p53, U2OS cells were
subjected to UV-induced DNA damage under conditions
known to elevate p53. As can be seen in Figure 2B, this
resulted in a significant decrease of NS. This result is con-
sistent with the interpretation that experimental elevation of
ARF (Figure 2A) may negatively impact NS via a stabiliza-
tion of p53.
It was next logical to ask whether NS modulates p53. As
shown in Figure 3A, knockdown of NS led to an elevation of
p53. Immunoblot analysis of these cells (Figure 3C) revealed
an 60% knockdown of NS and an approximately threefold
elevation of p53. To ask whether the increased p53 is func-
tional, we examined the level of MDM2 after NS knock-
down. Functional p53 acts as a transcriptional activator of
MDM2 gene expression, so an elevation of MDM2 protein
would imply functionality of the elevated p53. As can be
seen in Figure 3B, the level of MDM2 was indeed increased
in cells in which NS was knocked down, in support of the
hypothesis that the p53 induced by NS knockdown is func-
tional. We also investigated whether knockdown of p53
Figure 1. Down-regulation of nucleostemin by ARF expression. (A) U2OS cells were transfected with ARF-GFP or with ARF itself. After
24 h, NS was detected by immunostaining, and ARF was detected by immunostaining (right column) or by the fluorescence of ARF-GFP (left
column). (B) Control or ARF siRNAs were transfected into HeLa cells, and ARF and NS were detected by immunostaining 24 h later. (C)
Western blot performed 24 h after transfection of U2OS cells with vector DNA or the ARF-encoding plasmid. Transferrin receptor (TR) was
used to assess equivalence of cell extract loading.
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affects the level of NS and found that it does not (Supple-
mental Figure 2), indicating that NS acts as an upstream
regulator of p53.
A role of NS in cell cycle progression is indicated by the
fact that its depletion in U2OS cells reduces S phase entry,
that blastocysts or fibroblasts from NS / embryos dis-
play haploinsufficiency with respect to growth rate, and that
NS / blastocysts fail to enter S phase (Tsai and McKay,
2002; Beekman et al., 2006; Zhu et al., 2006). Based on our
finding that depletion of NS up-regulates p53, which
plays a key role in the surveillance of cell cycle progres-
sion, we hypothesized that the p53 pathway might be
involved in cell cycle arrest in NS-deficient cells. We
therefore investigated cell cycle progression in U2OS (p53
positive, Rb positive, and ARF negative) and Saos-2 cells
(p53 negative, Rb negative, and ARF negative) as a func-
tion of NS and p53 expression levels. Compared with cells
transfected with a control siRNA, knockdown of NS
caused a significant decrease in the percentage of cells
entering S phase in U2OS cells but not in Saos-2 cells
(Figure 4, A and B). These results thus suggest that NS
depletion-induced G1 cell cycle arrest may require p53. To
address this issue, p53 was knocked down in U2OS cells
(Supplemental Figure 2). As expected, this did not affect
the percentage of cells traversing S as these cells are
already cycling at a high rate (Figures 4C, left two col-
umns, and D). NS knockdown again reduced cell cycle
progression (Figure 4D). However, when p53 was knocked
down in addition to NS, the percentage of cycling cells re-
turned to the same high level as seen in control cells (Figure
4D), providing direct evidence that cell cycle arrest induced by
depletion of NS is mediated by the p53 pathway.
Figure 2. Down-regulation of NS coincides
with up-regulation of p53. (A) NARF6 cells (a
U2OS-derived ARF-inducible cell line) were
immunostained for p53 and NS after 48-h
treatment with 1 mM isopropyl--d-thiogalac-
topyranoside. (B) U2OS cells were subjected to
254-nm irradiation (10 J/cm2) to activate p53,
and then they were immunostained 16 h later
for p53 and NS.
Figure 3. Knockdown of NS leads to elevation of p53 and MDM2. Control or NS siRNAs were transfected into U2OS cells. (A) NS and p53
were detected by immunostaining after 48 h. (B) NS and MDM2 were detected after 48 h. (C) Western blot performed 48 h after transfection
with control or NS siRNAs.
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We next asked whether NS might also control cell cycle
through the Rb pathway. In contrast to our finding with p53,
we found that NS depletion-induced G1 arrest was not
rescued by Rb depletion (Figure 5, A and B, and Supple-
mental Figure 3), thus indicating that NS does not operate
via the Rb pathway, at least in U2OS cells.
p53 is a pivotal regulatory protein that evokes cell cycle
arrest in response to numerous stress signals including
hypoxia, nutrient depletion, heat shock, and DNA damage
(Vogelstein et al., 2000; Bensaad and Vousden, 2005; Vousden,
2006). Because these stimuli often trigger nucleolar disorgani-
zation and p53 activation, it has been suggested that the nu-
cleolus plays a role in modulating the cell cycle’s response to
stress (Rubbi and Milner, 2003; Horn and Vousden, 2004; Raska
et al., 2006). This idea has received additional support from the
finding that under such conditions the level of p53 can be
coordinated by a variety of nucleolar proteins, including the
ribosomal proteins S6, L5, L11, L23, and L26 as well as TIF-IA,
nucleolin, Bop1, B23 (nucleophosmin), ARF, PML, and WRN
(Blander et al., 1999; Pestov et al., 2001; Colombo et al., 2002;
Daniely et al., 2002; Lohrum et al., 2003; Bernardi et al., 2004; Dai
and Lu, 2004; Jin et al., 2004; Sulic et al., 2005; Takagi et al., 2005;
Yuan et al., 2005; Raska et al., 2006). It is also of interest to recall
that the nucleolus contains mitogenic growth factors such as
fibroblast growth factor and angiogenin (Pederson, 1999), an
observation that now might be productively revisited given the
Figure 4. Loss of p53 restores cell cycle progression in NS knocked down cells. (A) U2OS cells (p53 positive) and Saos-2 (p53 null) were
transfected with control or NS siRNAs, respectively, and 10 M BrdU was added 72 h later. After 24 h, the cells were sequentially
immunostained for NS and BrdU. (B) The percentages of cells that had incorporated BrdU were determined. Each bar indicates the mean 
SD of data from three independent experiments. (C) U2OS cells were transfected with control siRNA, control  p53 siRNAs, NS siRNA, or
NS  p53 siRNAs. BrdU (10 M) was added 72 h later and after another 24 h, the cells were immunostained for NS and BrdU. (D) Each bar
indicates the mean  SD of data from three independent experiments.
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connections that have been made among p53, Rb, and myc in
the nucleolus (Raska et al., 2006). In our experiments, NS de-
pletion did not lead to nucleolar disruption as judged either by
phase-contrast microscopy (see figures) or immunostaining for
the nucleolar marker proteins UBF, fibrillarin, and B23 (data
not shown). This suggests that NS depletion per se does not
constitute a nucleolar stress signal, notwithstanding the fact
that p53 is elevated in response to NS depletion as it is in other
situations in which nucleolar effects are observed. This consid-
eration supports the initial idea that NS and p53 operate pri-
marily through a nucleoplasmic interaction (Tsai and McKay,
2002, 2005). Nonetheless, it would now be all the more relevant
to track the dynamics and molecular interactions of NS, p53
and related proteins within the nucleus of living cells.
NS / mice abort before blastula and NS / fibro-
blasts display reduced NS levels and slower growth, but
normal levels of p53 (Zhu et al., 2006). In NS / fibro-
blasts, it is possible that the haploinsufficiency of NS as
regards optimal growth rate nevertheless does not result in
a depletion of NS sufficient to evoke the stabilization of p53.
Alternatively, NS may be operating in a p53-independent
manner. The possibility that NS can function via a p53-
independent pathway during embryogenesis is also indi-
cated by finding that p53 loss in NS / blastocysts does
not rescue embryonic lethality (Beekman et al., 2006). Based
on previous studies and the current investigation, it seems
plausible at present that there are p53-dependent and -inde-
pendent roles of NS in cell proliferation.
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